Introduction
Atherosclerosis develops and progresses at the arterial wall mediated by interactions between numerous growth factors, cytokines and vasoregulatory molecules that regulate cellular function with cells intrinsic to the vascular wall and extracellular matrix (ECM) as well as bloodborn cells and plasma constituents (1) . ECM fulfills diverse physiological roles in addition to providing structural support to tissues, and is a highly developed bioactive substance that helps to regulate the function of adjacent cells. In this review we focus on ECM present in plaque and outline its production and degradation as well as its contribution to plaque formation and progression.
ECM and Plaque Formation Collagen
The collagens, each molecule of which consists of three polypeptide chains termed α chains, make up the protein family which is the principal constituent of ECM. According to genome analysis published in February 2001, collagen triple helix repeat-coding genes number 106 (2). To date, based on the composition of these α chains, 25 types of collagen have been differentiated. Thirteen types of collagen are present in the vascular wall where they help to maintain the structural integrity of the vascular wall, enhance its flexibility, and in addition play a role in various cellular events including differentiation, adhesion, migration, proliferation, and apoptosis (3) . Collagen content increases in parallel with plaque formation and progression, and in collagen-rich plaque makes up to 60% of the total protein content (4) . Type I collagen accounts for 70% of all collagen, with immunohistochemical analysis of the distribution of individual collagen types in plaque providing interesting information (5) . Both types I and III collagen, which are fibrillar, are distributed together in all plaques (Fig. 1) , while type V collagen shows increasing stainability with lesion progression, with which it is closely related (Fig. 1) . Types I and III collagen are rigid and elastic respectively, while type V collagen, when abundant, forms thin fibers (6) . In this way, collagen fibers, with type I collagen as the base, by altering the proportion of types III and V collagen can meet various functional demands. Type IV collagen, which is the principal constituent of basement membrane, increases with lesion progression as well. Smooth muscle cells of the media and of early atherosclerotic lesions are surrounded by relatively thin type IV collagen, whereas in advanced lesions, smooth muscle cells are surrounded by multi-layered, thick type IV collagen (Fig. 1) , reaching a thickness of up to 10-fold that of the cell body (4). Thickening of the basement membrane reflects a decrease in the proliferative capacity of the cell and serves as an index of aging. These collagens also play a role in lipoprotein deposition, with oxidized LDL binding especially readily to types I, V, III, and IV collagens in decreasing order (7) . Type VI collagen is also inevitably present at sites of intimal thickening (Fig. 1) , and together with a cellular adhesion action, binding to type VI collagen, and binding to type III collagen and basement membrane type IV collagen adds to the structural integrity of plaque. Furthermore, although this collagen is degraded by human neutrophil elastase (8) , it shows resistance to various matrix-degrading enzymes released by cells such as smooth muscle cells and macrophages, and so plays a vital role in the strengthening and stabilization of plaque. Type VIII collagen assumes a hexagonal lattice structure, and enhances the elasticity of plaque by stabilizing the plaque structure and binding to elastic fibers (3) . The deposition of each collagen type changes with progression of the lesion, with this reflecting smooth muscle cell collagen metabolism. This smooth muscle cell collagen metabolism is regulated mainly by growth factors and cytokines. For example, transforming growth factor (TGF)-β enhances the synthesis of types I, III, IV and V collagen (9, 10), while conversely interleukin (IL)-1 (10), tumor necrosis factor (TNF)-α (11) and interferon (INF)-γ (9) suppress collagen synthesis. In addition, platelet-derived growth factor (PDGF) enhances the synthesis of types V and VIII collagen , while inhibiting that of type IV collagen (3, 12) . In this way, each collagen increases in parallel with evolution of the lesion, while extensive degradation of collagens occur in the lipid core. Cellular apoptosis and death, and elastin degradation in concert with lipid deposition lead to plaque weakening and fragility.
Elastic fibers
Elastic fibers are made up of the structural protein elastin and microfibrils. Elastic fibers are deposited in large numbers in plaque, making it elastic and resilient, but decrease in parallel with lipid deposition. Elastic fibers become the site of lipid and calcium deposition, with lipid deposition resulting in reduced elasticity and enhanced susceptibility to the action of elastin-degrading enzymes. Smooth muscle cells are the elastin-producing cells in plaque, although recently it has been reported that macrophages within plaque express both elastin soluble precursor tropoelastin mRNA and protein (13) . Smooth muscle cell elastin metabolism is regulated by growth factors and cytokines, with for example TGF-β (14) and insulin-like growth factor (IGF)-1 (15) promoting elastin synthesis, and conversely epidermal growth factor (EGF) (16) inhibiting it.
Glycoproteins
In addition to the glycoproteins such as laminin and entactin/nidogen that make up the basement membrane in plaque, fibronectin, thrombospondin, vitronectin, tenascin, and osteopontin are deposited as well. Fibronectin is an adhesive glycoprotein, which possesses the ability to bind to various other macromolecules including collagen, heparin/heparan sulphate, and fibrin, as well as to cells, and influences the proliferation, morphology, migration and differentiation of smooth muscle cells (17) .
Thrombospondin-1 is a glycoprotein produced by various cells including platelets, endothelial cells, smooth muscle cells, and macrophages. It promotes the proliferation and migration of smooth muscle cells (18) , and possesses a latent TGF-β activation action (19) . Thrombospondin-5 is localized around smooth muscle cells and possesses a migration promoting action (18) . Vitronectin also promotes smooth muscle cell migration mediated by αvβ3 and αvβ5 (20) . Osteopontin has a strong affinity for collagen, similarly promotes smooth muscle cell migration (21) . Recently, osteopontin was reported to accelerate fatty streak formation in mice fed a high-cholesterol diet (22) , suggesting its importance in plaque formation.
Proteoglycans
Proteoglycans are a group of complex macromolecules consisting of glycosaminoglycans (GAG) such as heparan sulfate, chondroitin sulfate, and dermatan sulfate, which are linked covalently to a core protein. They play various important roles in the vascular wall including organization of ECM structures and maintenance of viscoelastic properties, cell adhesion, cell migration and proliferation, permeability, hemostasis, thrombosis and lipid metabolism (17, 23) . Usually one type of GAG predominates on a single core protein, giving rise to four main families: chondroitin sulfate proteoglycans (CSPGs), dermatan sulfate proteoglycans (DSPGs), heparan sulfate proteoglycans (HSPGs), and keratan sulfate proteoglycans (KSPGs). Three major families of proteoglycans enriched in chondroitin sulfate, dermatan sulfate, and heparan sulfate have been identified in blood vessels and synthesized by vascular cells. Hyaluronan is not covalently linked to a core protein as are the other proteoglycans. Endothelial cells produce mainly HSPGs such as perlecan and CS/DSPGs such as biglycan, whereas smooth muscle cells produce mainly CSPGs such as versican and DSPGs such as biglycan and decorin.
There are regional differences in the distribution of hyaluronan and proteoglycans in the developing atherosclerotic plaque. Hyaluronan (24) , and versican, a large chondroitin sulfate proteoglycan (25) , are prominent in the intima of early developing plaques. Biglycan and decorin are both found in the fibrous caps of plaques (26) .
Chondroitin/dermatan sulfate proteoglycans (versican, biglycan, and decorin) that accumulate in plaque show a marked affinity for LDL and form an insoluble complex. This complex accelerates the oxidation of LDL (27) , facilitates phagocytosis by macrophages, induces the deposition and retention of LDL, as well as endothelial cell injury and smooth muscle cell proliferation/migration, thereby leading to further expansion of the plaque. Kolodgie et al (28) reported that in plaque associated with erosion and thrombus formation hyaluronan and versican showed strong stainability immunohistochemically, in contrast to biglycan and decorin, which stained only extremely weakly, and suggested the involvement of hyaluronan and versican in the onset of the acute coronary syndrome. They argued that hyaluronan acts to promote detachment of endothelial cells, and mediated by CD44 (hyaluronan receptor) expressed on the smooth muscle cell surface elicits platelet adhesion and aggregation, and polymerization of fibrin, thereby promoting thrombus formation.
Of the various growth factors and cytokines expressed in plaque, hitherto PDGF, TGF-β, and IL-1 have been reported to exert an influence on proteoglycan synthesis by vascular smooth muscle cells. Both PDGF and TGF-β increase production of versican and biglycan (17, 29) . IL-1 secreted by macrophages increases decorin synthesis (30), while inhibiting versican synthesis (31) by smooth muscle cells.
ECM degradation and matrix metalloproteinases
The matrix metalloproteinases (MMPs), also called matrixins, are thought to play a central role in degradation of the ECM components (32, 33) . The proteolytic activities of MMPs are precisely controlled during activation from their precursors and inhibited by endogenous inhibitors.
At present, the human MMP family is thought to consist of 25 members, which are classified into 5 groups according to differences in their primary structure and substrate specificity. Table 1 shows the substrate and producing cells in plaque of each MMP, indicating that almost all ECM components can be degraded by the MMPs produced locally by the cells in plaque.
Tissue inhibitors of metalloproteinase (TIMPs) are endogenous inhibitors specific to MMP, 4 of which (TIMP-1, 2, 3, 4) have hitherto been discriminated (32) . TIMP inhibits MMP activity at a molar ratio of 1:1. Moreover, TIMP-1 forms a complex with proMMP-9 and regulates its activation. Also, the intervention of TIMP-2 is essential for the activation of proMMP-2 by MT1-MMP. In this way, TIMP strictly regulates MMP activity, and in vivo only under conditions of MMP-TIMP imbalance (MMP activity predominance) is MMP activity manifested.
Degradation of ECM by MMP not only induces changes in its pre-existing three-dimensional structure, but also exerts an influence at various stages of plaque development (34) . For instance, MMP-2 and MMP-9 promote the migration and proliferation of smooth muscle cells, while monocytes and T-lymphocytes adhering to endothelial cells enhance the production of MMP-9 and MMP-2 respectively. This is associated with endothelial cell basement membrane degradation and penetration of the intima by monocytes and T-lymphocytes leading to enhanced endothelial cell permeability. This results in greater influx of plasma constituents including lipoproteins, thereby accelerating plaque formation and progression. Also, since various growth factors and cytokines bind to ECM and are retained there (35) , they are released and act when ECM is degraded by MMPs. Moreover, MMPs also degrade other factors including IL-1β, TNF-α, latent TGF-β, and heparin binding-epidermal growth factor (HB-EGF) (33) .
Recently, attention has been focused on ADAM (a disintegrin and metalloproteinase), which is a general term for proteases which possess multiple domains including a snake venom metalloproteinase domain and a disintegrin-like domain. More than 30 ADAM molecular types have been identified, and have been broadly divided into a membrane-type ADAM and secretory-type ADAMTS (33) . The membrane-type ADAM molecule attaches to the cell membrane via a disintegrin ligand domain, and is thought to be involved in the metabolism of growth factors and cytokines and differentiation-inducing factors present on the cell surface. Of the various ADAM molecules, ADAM-15 (MDC 15) mRNA is expressed on cultured human aortic smooth muscle cells, while enhanced expression of ADAM-15 protein has been demonstrated in hyperlipidemic monkey aortic plaque at sites where macrophages are copious (36) . ADAM-15 dependent on its RGD sequence has been reported to adhere to other cells specifically mediated by αvβ3 (37). ADAM-15 contains the metalloproteinase and disintegrinlike domains and by binding to αvβ3 integrin allows the former to degrade the ECM surrounding the cells that express αvβ3. These processes may be implicated in the development and progression of atherosclerosis. Further, ADAMTS molecules are involved in the degradation and metabolism of ECM components, with ADAMTS-1 and ADAMTS-4 reported to degrade versican deposited in human aortic plaque (38) . Another important task for future research will be to clarify the role of ADAM and ADAMTS in atherosclerosis.
Plaque instability and MMP
Since atherosclerosis is primarily a lesion that progresses due to a series of reactions that are induced by repair of injured intima (39, 40) , the synthesis and degradation of ECM are thought to be strictly controlled. However, due to the involvement of lipid, which is characteristic of this lesion, advanced plaque is divided into 2 portions: a fibrous cap making up the surface layer and a lipid core making up the deep layer. Large amounts of ECM are deposited in the fibrous cap, with the strength of the plaque maintained, whereas in the lipid core in addition to lipid deposition, ECM degradation is enhanced, leading to increased tissue fragility. This plaque fragility gives rise to plaque vulnerability in turn becoming a cause of plaque rupture (41) .
The authors have hitherto analyzed MMP-1, 2, 3, 7, 9, 12 and MT1-MMP which activate latent MMP-2 localized in plaque as well TIMP-1 and -2, which are inhibitors of MMP. Immunohistochemically, the numbers of MMP-1 and -9-positive macrophages and smooth muscle cells in plaque increase in parallel with plaque progression. Also, together with MMP-2, MT1-MMP has also been demonstrated in macrophages and smooth muscle cells. Fig. 2 shows the expression of MMP-2 and MT1-MMP mRNAs and gelatinolysis by in situ hybridization and in situ zymography, and from the figure it can be appreciated that at the shoulder region of the plaque, namely the border between the plaque and relatively normal tissue, gelatinolysis has occurred (the white portions in the lower panel of Fig. 2 indicating the spots where gelatin has actually been degraded). This finding shows that types I and III collagen, which form fibers in plaque, are degraded, with the resulting degenerative collagen (gelatin) then also degraded. Also, it has been proved that the cells playing the central role in the degradation of gelatin in the shoulder region of plaque are macrophages, with type I collagen degraded by MMP-1 and MMP-13 that are produced by these macrophages (42) . Attention has been drawn to the fact that both MMP-7 mRNA and protein are expressed primarily at the border between the fibrous cap and lipid core (Fig. 3) . Halpert et al. (43) have reported similar findings, noting that the degradation by MMP-7 especially of versican in the border area facilitates the separation of the fibrous cap from the lipid core. Both mRNA and protein of MMP-12, which possesses strong elastin degrading activity, were found in macrophages particularly at the border between the fibrous cap and lipid core.
As outlined above, MMPs are implicated in the weakening of plaque. In this context the recent findings of Lemaitre et al. (44) are of particular interest in that they demonstrate that the in vivo expression of MMP-1 in the macrophages of apo E knockout mice significantly decreases atherosclerotic lesion formation, suggesting that remodeling of the ECM of atherosclerotic lesions by MMP-1 may favorably affect atherosclerosis, by preventing or delaying the progression of these lesions. Aikawa (45) has emphasized the need for further studies to provide direct in vivo evidence linking the action of the MMP family collagenases with regulation of the collagen content of plaques, critical to the clinical complications of atherosclerosis. We share this view and consider that additional studies in vivo are needed to both more precisely define the roles of various MMPs in the atherosclerotic process and also to identify and develop new modalities to regulate them in the clinical setting so as to favorably influence the course of atherosclerosis.
Closing Remarks
Enhanced synthesis of ECM in plaque contributes to plaque stabilization, but at the same time causes luminal stenosis. On the other hand, enhanced degradation of ECM promotes weakening of plaque increasing its vulnerability to rupture that gives rise to clinical events. Rekhter (46) has argued with respect to collagen deposition in atherosclerosis that "too much collagen leads to arterial stenosis, while not enough collagen makes atherosclerotic plaque prone to rupture". It is undoubtedly true that the most desirable state in humans would be to have only the necessary ECM deposited at only the necessary sites in only the necessary amounts. Future efforts in this field must also be directed at developing new approaches to achieve these goals. 
